Bulk Inquiry
Bortezomib
- PS 341 - Velcade
- Optical Purity: Optically pure
- Soluble in DMSO
- MF: C19H25BN4O4
- MW: 384.24
Description
Bortezomib is a highly selective, reversible 26S proteasome inhibitor that blocks proteasomal protein degradation and is widely used as a reference compound for proteasome-dependent oncology research.
Inhibition of the proteasome disrupts regulated protein turnover, induces proteotoxic stress and can suppress NF-κB pathway activation by preventing IκB degradation. Bortezomib is especially relevant for studies of plasma-cell malignancies and apoptosis induction.
Key Features
- Reversible 26S proteasome inhibitor
- Disrupts ubiquitin-proteasome protein turnover
- Induces proteotoxic stress and apoptosis in sensitive tumor cells
- Clinically relevant reference compound in multiple myeloma research
Applications
- Proteasome and ubiquitin pathway studies
- Apoptosis and proteotoxic stress assays
- Multiple myeloma and B-cell malignancy models
- NF-κB signaling and protein degradation research
More Information
| Parent CAS No. | 179324-69-7 |
|---|---|
| Chemical Name | (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butan-2-ylboronic acid |
| SMILES | C1N=C(C(=O)N[C@@H](CC2C=CC=CC=2)C(=O)N[C@@H](CC(C)C)B(O)O)C=NC=1 |&1:6,17,r| |
| MFCD | N.A. |
| InChi | InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1 |
| InChiKey | GXJABQQUPOEUTA-RDJZCZTQSA-N |
| CID | 387447 |
| Short Description | Proteasome inhibitor |
References
- P Bonvini et al. Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia 2007, 21(4), 838–842.
- S Williams et al. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol. Cancer Ther. 2003, 2, 835-843.
- Y Ling et al. Mechanisms of Proteasome Inhibitor PS-341-induced G2-M-Phase Arrest and Apoptosis in Human Non-Small Cell Lung Cancer Cell Lines. Clin. Cancer Res. 2003, 9, 1145-1154.
- A Corso et al. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma. Leukemia & Lymphoma 2010, 51(2), 236-242.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1779 | WP 1130 |
From $104.50 |
| 1798 | Eeyarestatin I |
From $88.00 |
| 1869 | MG 132 |
From $88.00 |
| 1906 | P 22077 |
From $104.50 |
| 2011 | P 005091 |
From $104.50 |
| 2199 | ONX 0914 |
From $77.00 |
| 2228 | NSC 687852 |
From $99.00 |
| 2309 | ML 323 |
From $104.50 |
| 2333 | TCID |
From $88.00 |
| 2426 | SMURF1 inhibitor A01 |
From $126.50 |
| 2449 | LDN 57444 |
From $108.90 |
| 2512 | Spautin 1 |
From $104.50 |
| 2556 | MLN2238 |
From $93.50 |
| 2557 | MLN9708 |
From $104.50 |
| 3724 | M-3258 |
From Inquiry |
